Markus Augusti, president and CEO of orthopedics implant company Conformis, told investors during the J.P. Morgan Healthcare conference that the company is executing on its strategic pivot, announced in August, to develop and market “less-personalized” hip and knee products for treating patients in ambulatory care centers.
The trend toward moving knee and hip surgeries into the outpatient setting has been going on for some time. The Centers for Disease Control and Prevention added 11 procedures to the ambulatory surgical centers-covered procedures listing beginning on 1 January 2021, including total hip arthroplasty
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?